Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Programmed cell death receptor 1 (PD-1) and programmed death-ligand 1 (PD-L1) are key regulators of immune responses and targets in cancer immunotherapy.
• Current PD-1/PD-L1 blockade therapies face limitations, with a significant proportion of patients not responding, leading to a clinical plateau.
• Tumor immune escape is mediated by PD-L1 overexpression, which inhibits T cell activation via PD-1 binding.

Purpose of the Study:

• To review the role of PD-L1 post-translational modifications (PTMs) in regulating tumor immunity.
• To explore novel therapeutic strategies targeting PD-L1 PTMs to improve cancer immunotherapy efficacy.
• To summarize recent advancements in understanding PD-L1/PD-1 PTMs and their impact on immunotherapy.

Main Methods:

• Literature review and synthesis of research on PD-L1 post-translational modifications.
• Analysis of mechanisms underlying various PTMs of PD-L1, including glycosylation, ubiquitination, phosphorylation, acetylation, and palmitoylation.
• Examination of therapeutic strategies targeting PTMs and their associated enzymes.

Main Results:

• PD-L1 PTMs, including glycosylation, ubiquitination, phosphorylation, acetylation, and palmitoylation, significantly influence PD-L1 function and immune regulation.
• These modifications present potential targets for novel immunotherapeutic interventions.
• Research highlights mechanism-based therapeutic strategies involving enzymes and targets related to PD-L1 PTMs.

Conclusions:

• PD-L1 PTMs represent a critical area for improving the efficacy of existing PD-1/PD-L1 blockade therapies.
• Targeting specific PTMs offers promising new avenues for overcoming resistance and enhancing anti-tumor immunity.
• Further research into PD-L1/PD-1 PTMs is essential for advancing tumor immunotherapy strategies.